Automating Aetna Specialty Drug Prior Auth for Efficient Care Delivery

Klivira streamlines Aetna specialty drug prior auth, navigating the complex benefit split and diverse submission channels to accelerate access to critical therapies.

Managing prior authorizations for specialty drugs under Aetna policies presents unique challenges for revenue cycle directors and PA coordinators. The intricate split between medical and pharmacy benefits, coupled with specific submission requirements, often leads to delays and administrative burden. Klivira provides a robust solution designed to automate and optimize this critical workflow.

Navigating Aetna's Specialty Drug Prior Auth Channels

Aetna, including CVS Health Aetna, administers specialty drug prior authorizations across distinct channels depending on whether the medication falls under the medical or pharmacy benefit. Klivira's platform intelligently routes submissions to the correct pathway, whether through the Availity provider portal, X12 278 EDI, or dedicated ePA partners.

Aetna's Channel Specifics for Specialty Drug PA

**Medical Benefit Specialty Drugs:** For provider-administered injectables and infusions, Aetna routes medical-benefit precertification requests through the Availity provider portal. Klivira also supports X12 278 transactions via clearinghouses for applicable procedure categories.
**Pharmacy Benefit Specialty Drugs:** Outpatient retail and mail-order specialty drugs are administered via CVS Caremark, Aetna's PBM. Submissions for retail pharmacy PA route through ePA partners like CoverMyMeds or Surescripts, while mail-order and case-managed scenarios utilize CVS Caremark's direct provider portal.
**Benefit-Side Determination:** A critical first step, Klivira's policy engine automates the determination of whether a specialty drug falls under Aetna's medical or pharmacy benefit, preventing misclassification and routing errors.

Accessing Aetna's Specialty Drug Clinical Policies

Aetna's medical necessity criteria for specialty drugs are published as Clinical Policy Bulletins (CPBs) within their public CPB library. Klivira integrates with these policy sources, ensuring that submissions align with current, versioned, and dated criteria, including any specific step-therapy protocols published within applicable CPBs.

Streamlining Documentation for Aetna Specialty Drug PA

Specialty drug prior authorization requests for Aetna often require detailed clinical documentation, including diagnosis, prior-line therapy history, and site-of-care information. Klivira automates the extraction and population of this data from EMRs, utilizing FHIR MedicationRequest and Observation resources to ensure comprehensive and compliant submissions, addressing common denial reasons such as insufficient documentation or step-therapy gaps.

Klivira's Impact on Aetna Specialty Drug PA Turnaround Times

While Aetna's turnaround times are governed by state-specific regulations and NCQA UM accreditation standards, Klivira's automation reduces internal processing delays. For Aetna's Medicare Advantage and Medicaid lines of business, Klivira's electronic submission capabilities align with forthcoming CMS-0057-F requirements for 72-hour standard and 24-hour expedited decisions, improving efficiency ahead of phased compliance timelines.

Addressing Da Vinci PAS and Electronic Standards with Aetna

Klivira supports industry standards like NCPDP SCRIPT for pharmacy ePA and X12 278 for medical benefit submissions. While Aetna participates in HL7 connectathons, production conformance with Da Vinci PAS IG has not been independently verified. Klivira is designed to integrate with Da Vinci PAS when Aetna publicly confirms live support, ensuring future-proof connectivity.

Frequently asked questions

How does Aetna differentiate between medical and pharmacy benefit specialty drugs for prior authorization?

Aetna's administration of specialty drug prior authorization depends on the benefit category. Medical-benefit drugs (e.g., infused biologics) typically route through the Availity portal or X12 278. Pharmacy-benefit drugs (e.g., patient-administered oral therapies) are managed by CVS Caremark, with submissions via ePA partners like CoverMyMeds or Surescripts, or CVS Caremark's direct provider portal for specific scenarios.

Where can I find Aetna's specific clinical criteria for specialty drug prior authorization?

Aetna publishes its medical necessity criteria, including those for specialty drugs, in its public Clinical Policy Bulletins (CPBs) library. These CPBs are versioned and dated, providing the canonical identifier for policy citations. Klivira's platform references these CPBs to ensure compliance during the submission process.

Does Aetna support electronic prior authorization (ePA) for specialty drugs?

Yes, Aetna supports ePA, particularly for pharmacy-benefit specialty drugs through its PBM, CVS Caremark, leveraging partners like CoverMyMeds and Surescripts via NCPDP SCRIPT. For medical-benefit specialty drugs, electronic submissions are supported via X12 278 transactions and the Availity provider portal. Klivira integrates with these channels to facilitate comprehensive electronic submissions.

How does Klivira help with Aetna's step-therapy requirements for specialty drugs?

Klivira automates the documentation of prior-line therapy and treatment response by extracting relevant data from EMRs via FHIR. This ensures that Aetna's step-therapy protocols, which are published within applicable CPBs, are met and properly documented in the PA submission, reducing denials related to step-therapy gaps.

What impact does CMS-0057-F have on Aetna specialty drug prior authorization?

CMS-0057-F directly impacts Aetna's Medicare Advantage, Medicaid managed-care, CHIP, and QHP-on-FFM lines of business. This rule mandates specific decision timeframes (e.g., 72 hours for standard, 24 hours for expedited) and electronic PA API conformance. Klivira's automation capabilities help providers align with these requirements for impacted Aetna plans.